Format

Send to:

Choose Destination
See comment in PubMed Commons below
Epigenetics. 2013 Aug;8(8):785-95. doi: 10.4161/epi.25440. Epub 2013 Jun 27.

Epigenetic pathways and glioblastoma treatment.

Author information

  • 1Division of Biostatistics; Department of Epidemiology and Public Health; University of Miami Miller School of Medicine; Miami, FL USA.

Abstract

Glioblastoma multiforme (GBM) is the most common malignant adult brain tumor. Standard GBM treatment includes maximal safe surgical resection with combination radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. Alarmingly, patient survival at five-years is below 10%. This is in part due to the invasive behavior of the tumor and the resulting inability to resect greater than 98% of some tumors. In fact, recurrence after such treatment may be inevitable, even in cases where gross total resection is achieved. The Cancer Genome Atlas (TCGA) research network performed whole genome sequencing of GBM tumors and found that GBM recurrence is linked to epigenetic mechanisms and pathways. Central to these pathways are epigenetic enzymes, which have recently emerged as possible new drug targets for multiple cancers, including GBM. Here we review GBM treatment, and provide a systems approach to identifying epigenetic drivers of GBM tumor progression based on temporal modeling of putative GBM cells of origin. We also discuss advances in defining epigenetic mechanisms controlling GBM initiation and recurrence and the drug discovery considerations associated with targeting epigenetic enzymes for GBM treatment.

KEYWORDS:

drug discovery; epigenetics; glioblastoma; statistical modeling

PMID:
23807265
[PubMed - indexed for MEDLINE]
PMCID:
PMC3883781
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Write to the Help Desk